-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Ambrx Biopharma (NYSE:AMAM) Stock Price Up 3.6%
Ambrx Biopharma (NYSE:AMAM) Stock Price Up 3.6%
Ambrx Biopharma Inc. (NYSE:AMAM – Get Rating)'s share price rose 3.6% during mid-day trading on Friday . The stock traded as high as $2.02 and last traded at $1.99. Approximately 163,413 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 964,432 shares. The stock had previously closed at $1.92.
Wall Street Analysts Forecast Growth
Separately, Robert W. Baird dropped their price objective on shares of Ambrx Biopharma from $8.00 to $4.00 in a research report on Wednesday, October 19th.
Get Ambrx Biopharma alerts:Ambrx Biopharma Trading Up 3.6 %
The stock's fifty day moving average is $1.53 and its two-hundred day moving average is $1.65.
Institutional Investors Weigh In On Ambrx Biopharma
Large investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in Ambrx Biopharma by 0.8% during the 2nd quarter. FMR LLC now owns 3,857,679 shares of the company's stock valued at $10,223,000 after purchasing an additional 32,320 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Ambrx Biopharma by 91.5% during the 1st quarter. Renaissance Technologies LLC now owns 22,600 shares of the company's stock valued at $93,000 after acquiring an additional 10,800 shares during the last quarter. Finally, Royal Bank of Canada bought a new position in Ambrx Biopharma during the 3rd quarter valued at $46,000. 43.14% of the stock is owned by institutional investors and hedge funds.About Ambrx Biopharma
(Get Rating)
Ambrx Biopharma Inc, a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer.
Further Reading
- Get a free copy of the StockNews.com research report on Ambrx Biopharma (AMAM)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Ambrx Biopharma Inc. (NYSE:AMAM – Get Rating)'s share price rose 3.6% during mid-day trading on Friday . The stock traded as high as $2.02 and last traded at $1.99. Approximately 163,413 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 964,432 shares. The stock had previously closed at $1.92.
Ambrx Biopharma Inc.（纽约证券交易所代码：AMAM — Get Rating）的股价在周五午盘交易中上涨了3.6％。该股的交易价格高达2.02美元，最后一次交易价格为1.99美元。午盘交易中约有163,413股交易，较平均每日交易量964,432股下降了83％。该股此前收于1.92美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测增长
Separately, Robert W. Baird dropped their price objective on shares of Ambrx Biopharma from $8.00 to $4.00 in a research report on Wednesday, October 19th.
另外，罗伯特·贝尔德在10月19日星期三的一份研究报告中将Ambrx Biopharma股票的目标价格从8.00美元下调至4.00美元。
Ambrx Biopharma Trading Up 3.6 %
Ambrx Biopharma 交易价格上涨3.6％
The stock's fifty day moving average is $1.53 and its two-hundred day moving average is $1.65.
该股的五十天移动平均线为1.53美元，其两百天移动平均线为1.65美元。
Institutional Investors Weigh In On Ambrx Biopharma
机构投资者对 Ambrx Biopharma 进行了权衡
About Ambrx Biopharma
关于 Ambrx Biopharma
(Get Rating)
（获取评分）
Ambrx Biopharma Inc, a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer.
Ambrx Biopharma Inc是一家临床阶段的生物制剂公司，利用其专有的扩展遗传密码技术平台发现和开发工程精准生物制剂。其主要候选产品是 ARX788，一种抗HER2抗体药物偶联物（ADC），用于治疗乳腺癌、胃/胃食管交界癌和其他实体瘤的各种临床试验都在研究该产品，包括正在进行的治疗HER2阳性转移性乳腺癌和胃癌的2/3期临床试验。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Ambrx Biopharma (AMAM)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免费获取 StockNews.com 关于 Ambrx Biopharma（AMAM）的研究报告的副本
- MarketBeat Week 回顾 — 1/16 — 1/20
- Old Dominion 是否表明卡车运输正在刹车？
- 诺德斯特龙将对降价的恐惧带入零售业
- 埃克森美孚股票：距离买入点仅几步之遥
- 高股息收益的必和必拓认为中国将推动 “23” 的增长
Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Ambrx Biopharma Daily 的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Ambrx Biopharma及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧